Distinct transduction modes of arginine-rich cell-penetrating peptides for cargo delivery into tumor cells
- PMID: 21843610
- DOI: 10.1016/j.ijpharm.2011.08.001
Distinct transduction modes of arginine-rich cell-penetrating peptides for cargo delivery into tumor cells
Abstract
The application of cell-penetrating peptides (CPPs) for delivering various cargo molecules with biological functions into cells has gained much attention in recent years. However, the internalization mechanisms and delivery properties of CPP-cargo remains controversial. In this study, low- and high-molecular-weight cargoes attached to arginine-rich CPPs were employed: the former was the fluorescein isothiocyanate-labeled nona-arginine (CPP-FITC), and the latter was the fluorescently labeled nona-arginine-avidin complex (CPP-avidin). We measured the intracellular trafficking of CPP-FITC and CPP-avidin in four cancer cell lines in a series of microenvironments altered by the presence or absence of serum, different temperatures and different incubation times. The results revealed that CPP-cargo delivery exhibited no specificity toward any cell line, but the levels were found to be related to cell type and cargo. Furthermore, their endocytic mechanisms were investigated via incubation with related endocytic inhibitors. Two different types of CPP-cargo were required to cross the plasma membrane to bind to cell surface-associated heparan sulfate proteoglycans in a time-dependent manner. CPPs and small cargoes attached to CPP may enter cells rapidly via direct translocation in addition to the endocytic route. Translocation of large components linked to CPP tended to be mediated by macropinocytosis in an energy-dependent manner with slower rates for larger compounds. In contrast, the clathrin-dependent pathway is not essential to the translocation of either type of CPP-cargo.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
-
Identification and characterization of novel protein-derived arginine-rich cell-penetrating peptides.Eur J Pharm Biopharm. 2015 Jan;89:93-106. doi: 10.1016/j.ejpb.2014.11.020. Epub 2014 Nov 29. Eur J Pharm Biopharm. 2015. PMID: 25459448
-
Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides.Acc Chem Res. 2012 Jul 17;45(7):1132-9. doi: 10.1021/ar200256e. Epub 2011 Dec 30. Acc Chem Res. 2012. PMID: 22208383
-
CPP-protein constructs induce a population of non-acidic vesicles during trafficking through endo-lysosomal pathway.J Control Release. 2009 Oct 15;139(2):108-17. doi: 10.1016/j.jconrel.2009.06.028. Epub 2009 Jul 3. J Control Release. 2009. PMID: 19577599
-
Break on through to the other side-biophysics and cell biology shed light on cell-penetrating peptides.Chembiochem. 2005 Dec;6(12):2126-42. doi: 10.1002/cbic.200500044. Chembiochem. 2005. PMID: 16254940 Review.
-
On the importance of electrostatic interactions between cell penetrating peptides and membranes: a pathway toward tumor cell selectivity?Biochimie. 2014 Dec;107 Pt A:154-9. doi: 10.1016/j.biochi.2014.07.022. Epub 2014 Aug 5. Biochimie. 2014. PMID: 25107405 Review.
Cited by
-
Cell Penetrating Peptides, Novel Vectors for Gene Therapy.Pharmaceutics. 2020 Mar 3;12(3):225. doi: 10.3390/pharmaceutics12030225. Pharmaceutics. 2020. PMID: 32138146 Free PMC article. Review.
-
Cell-type specific penetrating peptides: therapeutic promises and challenges.Molecules. 2015 Jul 20;20(7):13055-70. doi: 10.3390/molecules200713055. Molecules. 2015. PMID: 26205050 Free PMC article. Review.
-
Deepened cellular/subcellular interface penetration and enhanced antitumor efficacy of cyclic peptidic ligand-decorated accelerating active targeted nanomedicines.Int J Nanomedicine. 2018 Sep 19;13:5537-5559. doi: 10.2147/IJN.S172556. eCollection 2018. Int J Nanomedicine. 2018. PMID: 30271146 Free PMC article.
-
Transporting carriers for intracellular targeting delivery via non-endocytic uptake pathways.Drug Deliv. 2017 Dec;24(sup1):45-55. doi: 10.1080/10717544.2017.1391889. Drug Deliv. 2017. PMID: 29069996 Free PMC article. Review.
-
Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system.Int J Nanomedicine. 2017 Mar 28;12:2385-2405. doi: 10.2147/IJN.S129574. eCollection 2017. Int J Nanomedicine. 2017. PMID: 28405163 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources